516 related articles for article (PubMed ID: 29258077)
1. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.
Kudo M
Oncology; 2017; 93 Suppl 1():135-146. PubMed ID: 29258077
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
3. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
4. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
6. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
Lai JM; Hu S; Lin H; Luo H; Luo YB
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.
Kudo M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30380773
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for liver cancer: updated review in 2012.
Kudo M
Curr Cancer Drug Targets; 2012 Nov; 12(9):1062-72. PubMed ID: 22920326
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
[TBL] [Abstract][Full Text] [Related]
11. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
12. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
13. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
Moriguchi M; Umemura A; Itoh Y
Clin J Gastroenterol; 2016 Aug; 9(4):184-90. PubMed ID: 27401471
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
15. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
16. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Kudo M
Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
[TBL] [Abstract][Full Text] [Related]
17. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Kim HY; Park JW
Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
